RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 -- It is with deep sadness that Pappas Capital announces the passing of Dr. Ernest Mario, Senior Venture Partner and one of the founders...
Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program
News | 07. 06. 2016
Syndax Pharmaceuticals
WALTHAM, Mass., July 6, 2016 – Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016.
